Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
NCT01037478
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Hodgkin's Lymphoma
Interventions
DRUG:
Resminostat (4SC-201)
Sponsor
4SC AG